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Abstract
A class of disulfide constrained peptides containing a core motif FPWG was identified from a screen of phage displayed library using
the HCV RNA-dependent RNA polymerase (NS5B) as a bait. Surface plasmon resonance studies showed that three highly purified synthetic
constrained peptides bound to immobilized NS5B with estimated Kd values ranging from 30 to 60 M. In addition, these peptides inhibited
the NS5B activity in vitro with IC50 ranging from 6 to 48 M, whereas in contrast they had no inhibitory effect on the enzymatic activities
of calf thymus polymerase , human polymerase , RSV polymerase, and HIV reverse transcriptase in vitro. Two peptides demonstrated
conformation-dependent inhibition since their synthetic linear versions were not inhibitory in the NS5B assay. A constrained peptide with
the minimum core motif FPWG retained selective inhibition of NS5B activity with an IC50 of 50 M. Alanine scan analyses of a
representative constrained peptide, FPWGNTW, indicated that residues F1 and W7 were critical for the inhibitory effect of this peptide,
although residues P2 and N5 had some measurable inhibitory effect as well. Further analyses of the mechanism of inhibition indicated that
these peptides inhibited the formation of preelongation complexes required for the elongation reaction. However, once the preelongation
complex was formed, its activity was refractory to peptide inhibition. Furthermore, the constrained peptide FPWGNTW inhibited de novo
initiated RNA synthesis by NS5B from a poly(rC) template. These data indicate that the peptides confer selective inhibition of NS5B activity
by binding to the enzyme and perturbing an early step preceding the processive elongation step of RNA synthesis.
© 2003 Elsevier Science (USA). All rights reserved.
Introduction
The hepatitis C virus (HCV) is the major etiological
agent of transfusion-acquired non-A, non-B hepatitis (Alter
and Mast, 1994; WHO, 1996). Approximately 4 million
people in the United States and 170 million people world-
wide are infected with HCV (WHO, 1996). About 15% of
those infected will spontaneously resolve the disease, but
85% with acute asymptomatic infection will progress to
chronic hepatitis, of which 20% will develop cirrhosis that
can progress to hepatocellular carcinoma (Farci et al.,
1992). Currently, the best available therapy for HCV infec-
tion is the combination therapy of pegylated interferon and
ribavirin, which is effective in only up to half of the patients
evaluated (McHutchinson et al., 1998; Poynard et al., 1998).
Therefore, there is a clinical need to develop efficacious
specific therapies against this virus. To a large degree,
studies on the biology of the virus has been limited due to
the lack of an efficient cell-culture system for viral propa-
gation, intrinsic low level of viral replication, and the ge-
netic diversity associated with the virus. The development
of a subgenomic HCV replicon in cell culture (Blight et al.,
2000; Lohmann et al., 1999, 2001), as well as an animal
model which consists of immunodeficient scid mice with
transplanted chimeric human livers (Mercer et al., 2001),
will prove useful to evaluate potential drug candidates that
inhibit replication of the virus.
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Our current understanding of the function of viral en-
coded proteins has been derived from in vitro studies (Bar-
tenschlager and Lohmann, 2000; Reed and Rice, 2000). The
HCV genome consists of a positive-strand linear RNA of
about 9.4 kb (Choo et al., 1991; Kato et al., 1990). It
encodes a single open reading frame that is preceded by an
untranslated region (UTR) of 341 nucleotides at the 5 end,
and the 3 end containing a variable region, a poly (U/C)
tract, and a 98 tail (Kolykhalov et al., 2000; Tanaka et al.,
1996; Yamada et al., 1996). The polyprotein, comprising
3010–3040 amino acids, is processed co- and posttransla-
tionally by cellular and viral proteinases into at least 10
mature polypeptides (Bartenschlager et al., 1993; Grakoui et
al., 1993a; Tanji et al., 1995; Tomei et al., 1993). The
polyprotein contains the following order of proteins: NH2-
C-E1-E2-p7-NS2-NS3-NS4A-NS4B-NS5A-NS5B-COOH
(Grakoui et al., 1993b; Tomei et al., 1993). Among these
viral proteins, the HCV RNA-dependent RNA polymerase
(NS5B) has been the major focus of investigation since it is
an attractive target for antiviral intervention. Our current
understanding of the function of viral-encoded proteins has
been derived from in vitro studies (Bartenschlager and
Lohmann, 2000; Reed and Rice, 2000). However, further
studies on adaptive amino acid substitutions of these pro-
teins generated during passage of the HCV subgenomic
replicon in hepatic cells could potentially reveal information
on genetic interactions among viral and host proteins
(Blight et al., 2000; Lohmann et al., 2001).
Although our knowledge of the mechanism of HCV
replication in the viral life cycle is limited, studies on other
plus-strand RNA viruses suggest that the positive RNA
strand genomic RNA serves as a template for synthesis of
the minus RNA strand (antisense). The minus RNA strand,
in turn, serves as the template for synthesis of multiple
copies of the progeny plus strands that are subsequently
packaged into virions (Porter, 1993; Strauss and Strauss,
1986; Wimmer et al., 1993). Studies using highly purified
preparations of the full-length NS5B polymerase have re-
vealed some biochemical features of the catalytic properties
of the enzyme (Behrens et al., 1996; Lohmann et al., 1998).
Recent studies have shown that removal of the C-terminal
21 acid hydrophobic tail of the enzyme resulted in a soluble
protein that is catalytically more active when compared to
the full-length enzyme (Carroll et al., 2000; Tomei et al.,
2000). The enzyme can catalyze complementary-strand
RNA synthesis from a self-primed single-stranded nonviral
RNA template by a “copy-back” mechanism to form a
duplex RNA hairpin (Behrens et al., 1996; Carroll et al.,
2000; Labonte et al., 2002) and can utilize short oligonu-
cleotide-primed RNA template for complementary-strand
RNA synthesis (Ferrari et al., 1999; Zhong et al., 2000). In
addition, the enzyme can catalyze de novo synthesis from a
nonprimed template, which may have implications for ini-
tiation of HCV genome replication (Kao et al., 2000; Luo et
al., 2000; Zhong et al., 2000). The crystal structure of the
enzyme indicates that the canonical palm, fingers, and
thumb domains are conserved among other polymerases
(poliovirus 3D-pol and HIV-reverse transcriptase). How-
ever, the HCV polymerase contains an additional structure
that encircles the active site. This peculiar structure has also
recently been observed on the distantly related double-
strand RNA polymerase of bacteriophage 6 and is likely to
influence the mechanism of replication (Ago et al., 1999;
Bressanelli et al., 1999; Lesburg et al., 1999; Butcher et al.,
2001).
In this study, we used phage-displayed peptide technol-
ogy to identify small peptides that bind to NS5B and inhibit
its function. The utility of the phage-display technology has
been exemplified in applications for the identification of
protein:protein contact sites (Hoess et al., 1993), peptide
mimics of nonpeptide ligands (Devlin et al., 1990; Hoess et
al., 1993; Oldenburg et al., 1992; Scott et al., 1992), and for
mapping of epitopes (Cwirla et al., 1990; Felici et al., 1991;
Scott and Smith, 1990). In addition, protein variants with
altered affinity or specificity have been isolated from librar-
ies of random mutants (Choo and Klug, 1995; Roberts et al.,
1992; Soumillion et al., 1994). We report here for the first
time a class of constrained peptides that bind to and pref-
erentially inhibit the activity of the HCV polymerase. Our
analysis indicates that these peptides inhibit a step in the
formation of a preelongation complex by the enzyme and
the 3OH end of the RNA substrate. Peptide ligands that
interact with specific sites on polymerase can serve as a
valuable tool to study mechanism of enzyme function, as
well as for target validation and the development of a
high-throughput screen assay.
Results
Identification of peptides that bind to NS5B
To maximize the chance of identifying peptides that bind
to NS5B polymerase, a C-terminal hexahistidine-tagged
version lacking the C-terminal 21 amino acid residues was
purified to homogeneity in a biologically active nonaggre-
gated form. Fig. 1A shows a Coomassie dye stained gradi-
ent SDS–PAGE (4–20%) of the final protein preparation.
Lanes 1 and 8 contain molecular weight markers, whereas
lanes 2–7 contain increasing amounts of the protein ranging
from 2.5 to 40 g. At the highest concentration used, only
a 66-kDa band corresponding to NS5B (del 21-His) was
detected, which illustrates the near homogeneity of the
protein preparation. In addition, sucrose gradient density
analysis revealed that the NS5B sedimentation profile was
consistent with the protein being monomeric in solution
(data not shown).
The purified enzyme was assayed for its ability to cata-
lyze RNA synthesis using a 369–nt RNA substrate called
pOF1213 (57) by a copy-back mechanism as reported pre-
viously by others (Bartenschlager and Lohmann, 2000;
Butcher et al., 2001) and as described under Materials and
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methods. Fig. 1B shows the yield of 33P-labeled product
increased linearly as a function of enzyme concentration
over 2 h. A time course of product formation using 24 nM
of enzyme over 120 min in Fig. 1C shows that the product
yield is biphasic, with a slow increase over the first 40 min,
followed by an increase in the rate from 40 to 120 min. As
will be shown later, this first slow phase may indicate a slow
rate of preelongation complex formation between NS5B and
the dinucleotide self-primed hairpin substrate. These results
indicate that the highly purified polymerase preparation was
active in catalyzing copy-back RNA synthesis of a
pOF1213 self-primed template.
This enzyme preparation was used to isolate peptide
ligands from a heptamer-constrained phage-displayed li-
brary as described under Materials and methods. For the
panning experiments, the purified protein was immobilized
on polystyrene plates via an interaction of its C-terminal
hexahistidine with the immobilized Ni2 so that the poly-
merase would be oriented to the phage-displayed peptides in
solution. After the binding reaction, the wells were blocked
with BSA to minimize the recovery of plastic interacting
peptides. After the third cycle of panning, phage DNA were
isolated from individual plaques and sequenced to deduce
the displayed peptides. The results of the sequence of nine
constrained heptamer peptides recovered are shown in Fig
2. The sequence alignment of these peptides revealed the
presence of a conserved FPWG motif. For subsequent ex-
periments, we have focused on the first three peptides based
on their profiles of binding and inhibition of NS5B.
Analysis of the binding of peptides to NS5B by Biacore
Since the experiments above suggested that the peptides
displayed as part of the pIII coat protein of the phage head
can bind to NS5B, we evaluated whether highly purified
preparations of these disulfide-constrained heptameric pep-
Fig. 1. Purified HCV NS5B is active in catalyzing RNA synthesis using a 396-nucleotide self-primed pOF1213 RNA substrate. (a) Purified HCV NS5B
polymerase. Increasing amounts of purified polymerase were subjected to electrophoresis on a SDS–PAGE (4–20%). The gel was stained with Coomassie
blue R. The arrow indicates the position of the NS5B protein (66 kDa); molecular weight markers (Bio-Rad) were used in the outer lanes. (b) Graph of pmol
of GMP incorporated into product, as a function of NS5B concentration (nM). Increasing concentrations of polymerase were incubated with 10 nM pOF1213
RNA substrate, 100 M rATP, rUTP, rCTP, and 5 M rGTP and 1.25 Ci [33P]rGTP for 2 h at room temperature. The pmol of GMP incorporated into
product was determined as described under Materials and methods. (c) Graph of pmol GMP incorporated at a fixed concentration of NS5B as a function of
time. 24 nM of the enzyme was incubated with the same amounts of substrates indicated above and the yield of product determined at 20-min intervals over
120 min as described above.
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tides could bind to NS5B in vitro. The nomenclatures of the
purified synthetic peptides as well as their corresponding
sequences used in this study are shown in Table 1.
The interactions of a representative subset of these pep-
tides with the NS5B protein were evaluated by the Biacore
surface plasmon resonance. Our initial strategy for the Bia-
core experiments was to immobilize the C-terminal biotin-
ylated peptides to a streptavidin-coated CM5 chip and to
measure its interaction with the polymerase in solution.
Unfortunately, the NS5B interacted strongly and nonspe-
cifically with the chip, thus precluding the use of this ana-
lytical approach. Therefore, we used an alternative approach
in which the HCV polymerase and human serum albumin
(as a negative control) were immobilized in separate chan-
nels and subsequently challenged with increasing concen-
trations of peptides. For these experiments, the peptides
were injected over a range of concentration from 10 to 100
M over the channels and the Kds and stoichiometry of
binding were estimated by fitting with the steady-state af-
finity model included in the Biacore Evaluation software.
As shown in Figs. 3A, B, and C, respectively, peptides KEY
(S-S), NTW (S-S), and NQW (S-S) bound with varying
affinities (Kd ranging from 33 to 56 M) to the enzyme with
a stoichiometry consistent with a 1:1 binding event. Inter-
estingly, the linear version of NQW peptide also bound to
HCV polymerase with a Kd value of 64 M (Fig. 3C).
These peptides did not exhibit any specific interaction with
immobilized human serum albumin (data not shown). The
fits for these peptides all indicate that the stoichiometry of
the significant binding event was 1:1. However, at higher
peptide concentrations, there were indications of additional
weaker nonspecific interactions with the enzyme. Taken
together, the data suggest that these four peptides interacted
with the NS5B polymerase in vitro.
Constrained peptides preferentially inhibited
the HCV RdRp
Since these peptides bound to NS5B, we assessed
whether they can inhibit NS5B activity in vitro. Moreover,
if they were highly selective for NS5B, we would expect
them to be significantly less potent in inhibiting the enzy-
matic activities of other polymerases, which are known to
contain conserved structural elements. The enzymes used in
this study included HIV reverse transcriptase, calf thymus
polymerase , human polymerase , and RSV polymerase.
DTT was omitted from these assays to maintain the integrity
of the disulphide-constrained peptides during the reaction.
In addition, the assays contained high concentrations of
BSA (50 g/ml, see Materials and methods) that would
mitigate any inhibition due to nonspecific interactions of the
peptide with proteins.
The constrained and linear versions of the peptides
NTW, KEY, NQW, and the core motif (FPWG) were syn-
thesized and evaluated in the assays described above. These
peptides were titrated in the assays over a range from 0.146
to 150 M and their IC50 values determined. As shown in
Table 2, the constrained peptide with the core motif inhib-
ited only the HCV polymerase with an IC50 value of 50 M.
Peptides NTW (S-S), KEY (S-S), and NQW (S-S) inhibited
the NS5B assay with IC50 values ranging from 6 to 22 M,
but they had values of 139 M for DNA polymerases and
HIV reverse transcriptase. Interestingly, peptide NQW
(S-S) also inhibited the RSV polymerase, another RNA-
dependent RNA polymerase. However, replacing Q with T
rendered the peptide, NTW (S-S), highly specific for HCV
polymerase. Also, the linear version of these peptides, NTW
Table 1
Summary of peptide sequences and their nomenclature used in this study
Name Peptide sequence
NTW (S-S) ACFPWGNTWCGGK (constrained)
NTW (L) ACFPWGNTWCGGK (linear)
KEY (S-S) ACFPWGKEYCGGK (constrained)
KEY (L) ACFPWGKEYCGGK (linear)
NQW (S-S) ACFPWGNQWCGGK (constrained)
NQW (L) ACFPWGNQWCGGK (linear)
FPWG (S-S) CFPWGC (constrained)
FPWG (L) CFPWGC (linear)
Note. The indicated disulfide-constrained peptides or their linear coun-
terparts were synthesized with an additional A and an additional GGK at
their N- and C-terminal ends, respectively. To simplify the nomenclature,
peptides were designated by the three amino acids adjoining the FPWG
motif. Constrained or linear peptides were designated as (S-S) or (L),
respectively.
Fig. 2. Alignment of the 7-mer disulfide-constrained peptides deduced
from phage clones isolated from a phage-displayed library. After the third
panning, the eluted phage particles were plated, and 40 independent
plaques were amplified in E. coli and the phage DNA was isolated and the
displayed peptide sequences were deduced following determination of the
N-terminal sequence of the recombinant PIII. Based on the profiles of
binding and inhibition, the first three peptides in bold were chosen for
further characterization in this study.
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(L) and KEY (L), had an IC50  150 M in all the poly-
merase assays, indicating that the constrained structure con-
ferred selective inhibition of these peptides in the NS5B
assay. Surprisingly, the NQW (L) was inhibitory in the
NS5B assay (IC50  37 M), but not in the other assays
(with IC50  150 M). At this point, we are uncertain
whether this peptide is inhibiting the assay by a mechanism
similar to its constrained peptide counterpart. Taken to-
gether, there is a good correlation between the binding
affinity of the peptides and their selective inhibition of the
HCV polymerase.
Identification of residues critical for the inhibitory effect
of the NTW (S-S) peptide
One of the bioactive peptide NTW (S-S) was chosen as
a prototype to identify residues that are essential for its
inhibitory activity. Constrained synthetic peptides in which
each of the F, P, W, G, N, T, and W residues were substi-
tuted for an A (Ala scan) were designated as F1A, P2A,
W3A, G4A, N5A, T6A, and W7A, respectively. The IC50
for each peptide was evaluated in the HCV polymerase
assay as described previously, and the data are shown in
Fig. 3. Analysis of HCV NS5B and peptide interactions using the Biacore surface plasmon resonance technology. The HCV polymerase and human serum
albumin were immobilized on separate chambers of the CM5 chips by amine coupling, and then increasing concentrations of the constrained and linear
version of peptides were analyzed for their ability to interact with the enzyme as described under Materials and methods. The graphical relationship of moles
bound peptide/moles immobilized NS5B ratio as a function of the respective M peptide concentrations are shown for peptides KEY (S-S) (A), NTW (S-S)
(B), NQW (S-S), and NQW (L) (C). The estimated Kd values for these peptides are also indicated.
Table 2
Effects of peptides on polymerase assays
Name Peptide sequence HCV pol HIV-RT c-pol  h-pol  RSV pol
NTW (S-S) ACFPWGNTWCGGK (S-S) 13.0 150 150 150 150
NTW (L) ACFPWGNTWCGGK (linear) 150 150 150 150 150
KEY (S-S) ACFPWGKEYCGGK (S-S) 22.0 150 150 150 123
KEY (L) ACFPWGKEYCGGK (linear) 150 150 150 150 150
NQW (S-S) ACFPWGNQWCGGK (S-S) 6.0 150 149 139 53.0
NQW (L) ACFPWGNQWCGGK (linear) 37.0 150 150 150 150
FPWG (S-S) CFPWGC (S-S) 50.0 150 150 150 150
FPWG (L) CFPWGC (linear) 150 150 150 150 150
Note. Peptides were titrated into the various enzyme assays (HCV polymerase, HIV reverse transcriptase, calf thymus polymerase , human polymerase
, and RSV polymerase) at final M concentrations of 0.29, 0.58, 1.17, 2.34, 4.69, 9.40, 18.75, 37.5, 75, and 150 in duplicates. The yield of RNA synthesis
was quantitated. The numbers represent IC50 values as described under Materials and methods.
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Fig. 4. When compared to the unsubstituted control peptide
(IC50  10 M), the A substitution at F1 within the core
motif resulted in a significant loss of inhibitory activity as
reflected in an IC50 of 200 M. The A substitution at W7
also resulted in a dramatic reduction in inhibition with an
IC50 of 80 M, which is eightfold less than the parent
peptide. The A substitution at P2, W3, and N5, respectively,
also resulted in approximately fourfold reduction of activity
compared to the parent peptide, whereas the substitutions at
G4 and T6 had no effect. These data indicate that F1 within
the core motif is essential for the inhibitory effect of the
NTW (S-S) peptide, although other residues within the
heptamer provide synergy to the inhibitory profile of the
molecule.
Peptides inhibit an early step in the function of the HCV
polymerase: primer template ternary complex
Based on our current understanding of the reaction path-
ways of a number of polymerases, the HCV NS5B poly-
merase likely assembles at the 3OH end of the self-primed
RNA substrate to form a preelongation complex. Thereafter,
the enzyme can catalyze complementary-strand synthesis
using the pool of the four ribonucleotide triphosphates to
yield a copy-back product. To define a step of the reaction
pathway inhibited by the peptides, we used a “burst kinetic”
assay that measures the yield of products and the rate of
elongation carried out by the enzyme primer:template com-
plex in one round of RNA synthesis from the pOF1213
substrate. For this experiment, the reaction was staged so
that the polymerase was prebound to the dinucleotide self-
primed substrate to enrich for the “preelongation complex,”
followed by the addition of rNTPs (Km) and heparin to
restrict the polymerase to one round of RNA replication
(Tomei et al., 2000; Butcher et al., 2001) . Heparin prevents
loading of the enzyme onto the template, during the course
of RNA synthesis process.
Fig. 5A shows a plot of the picomoles of GMP incorpo-
rated into product as a function of time of preincubation of
polymerase with pOF1213 from 1 to 4 h, in burst reactions
sampled in intervals from 1 to 10 min. An analysis of the
size of products derived from timed burst reactions after
preincubation of the enzyme and pOF1213 for 4 h is shown
in Fig. 5B. Together, the data indicate that the yield of
product increased linearly with time of preincubation from
1 to 4 h, implying that formation of the preelongation
complex is a slow process under these conditions. The burst
of RNA synthesis was completed in 5 min, with conversion
of the pOF1213 to a copy-back product twice its size,
suggesting that the enzyme synthesized RNA at about 68
nts/min at room temperature. We observed a 1-min lag of
synthesis, which could be due to incorporation of the 83 U’s
(nonradioactive) that preceded incorporation of the first
labeled [33P] GMP into the template.
It is conceivable that the peptides could affect preelon-
gation complex formation, or the elongation reaction cata-
lyzed by the enzyme. To discriminate between these two
possibilities, we designed two experiments using a 4-h pe-
riod of preincubation of template with the enzyme, with
different orders of peptide addition (see Table 3). In the
“peptide prebinding” experiment, the peptide was preincu-
bated with the polymerase and RNA template for 4 h, and
the reaction was initiated with NTPs for 15 min, a time
sufficient for a complete burst. The data of IC50 indicate that
the constrained peptides NTW (S-S), KEY (S-S), and NQW
(S-S) were inhibitory in the assay with IC50 of 8.4, 39.1, and
8.82 M, respectively. These IC50 values correlated with
the IC50 obtained in the straight incubation assay that was
carried out in excess substrates (see Table 2).
The results above suggest that the peptides may inhibit
the formation of the preelongation complex, or an event
required for its transition to the elongation complex. To
address whether the peptides can inhibit the processive
elongation reaction catalyzed by polymerase, a “peptide
postbinding” experiment was done. The enzyme was prein-
cubated with the RNA template for 4 h to form the active
preelongation complex, followed by the addition of peptides
and incubation for 15 min. Subsequently, rNTPs were added
to the reactions followed by incubation for 15 min. The
results from this experiment showed that these peptides at a
concentration of 150 M had no significant effect on the
burst assay. These data led us to conclude that once the
preelongation complex was formed, it became refractory to
inhibition by the peptides. Therefore these peptides appear
to inhibit the formation of the preelongation complex, but
not the elongation reaction catalyzed by the enzyme.
Peptide NTW (S-S) inhibits de novo synthesis using
poly(C) as a template
In vivo, the replication of the HCV viral genome is likely
to be initiated in the absence of primer by a de novo
mechanism (Kao et al., 2000; Luo et al., 2000; Zhong et al.,
2000). We have recently shown that the NS5B polymerase
Fig. 4. Profile of Alanine scan analysis of the NTW (S-S) peptide with
respect to inhibition of HCV polymerase. Peptides containing the appro-
priate alanine substitutions in the heptamer residues as indicated were
tested for their ability to inhibit the NS5B enzyme as described previously
in Table 2. The mean IC50 values of the corresponding peptides are
indicated along with the control parent peptide NTW (S-S).
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can catalyze de novo initiation of RNA synthesis using a
poly (C) RNA substrate with rGTP (Labonte et al., 2002).
Using this assay, the NTW (S-S) peptide was evaluated for
its ability to inhibit this reaction catalyzed by NS5B as
described under Materials and methods. The results shown
in Fig. 6 show that the peptide inhibited the de novo reaction
with an IC50 of 10 M, which is similar to that obtained in
the assays using the self-primed pOF1213 RNA substrate.
Since the peptide NTW (S- S) did not inhibit the elongation
process as shown previously, it is likely that the peptide
interferes with the formation of a preinitiation complex with
NS5B and the 3OH end (nonprimed) of the poly(C) tem-
plate.
Discussion
In this study, we have identified for the first time a class
of heptamer-constrained peptides from a phage-displayed
library screen using HCV NS5B polymerase as bait. These
peptides contained a core motif FPWG at the N-terminal
region of the sequence. BIACORE SPR analysis showed
that NTW (S-S), KEY (S- S), and NQW (S-S) bound to the
enzyme, consistent with a 1:1 ratio at low concentrations,
with apparent Kd ranging from 33 to 64 M. However, at
higher peptide concentrations, NQW (S-S) showed evi-
dence of additional weaker binding events, which could
easily represent nonspecific interactions. Their contribution
Fig. 5. Burst assay catalyzed by NS5B polymerase. (A) Graph showing pmol GMP incorporated as a function of time of burst RNA synthesis after a time
course of preincubation of NS5B with pOF1213 RNA substrate. 48 nM of the HCV polymerase was preinubated with 20 nM of the pOF1213 substrate in
25 l of reaction buffer in the absence of nucleotide triphosphates for 0.5, 1, 2, 3, and 4 h at room temperature. Thereafter, each reaction was made up to
50 l with the addition of 100 M ATP, UTP, CTP, and 5 M GTP and 10 Ci [33P]rGTP and 0.4 ng/ml heparin. The reactions were terminated at 0.5,
1, 2, 1.5, 2, 3, 5, and 10 min with EDTA to a final concentration of 83 mM and processed as described under Materials and methods. (B) Gel analysis of
denatured products derived from reactions sampled in a time course of burst RNA synthesis. The reactions were assembled as described above except that
the enzyme was preincubated with pOF1213 for 4 h and the burst reactions were terminated as indicated. The RNA was recovered from samples and subjected
to agarose gel electrophoresis as described under Materials and methods. Lane 1 contains the labeled pOF1213 RNA substrate shown by the arrow and lane
12 contains 33P-labeled RNA standards. The arrow pointing to the band in lane 11 indicates the position of the copy-back product.
Table 3
Effects of peptides on the burst assays catalyzed by HCV polymerase
Name Peptide sequence Prebinding Postbinding
NTW (S-S) ACFPWGNTWCGGK (S-S) 8.4 150
KEY (S-S) ACFPWGKEYCGGK (S-S) 39.1 150
NQW (S-S) ACFPWGNQWCGGK (S-S) 8.82 150
Note. The indicated peptides were tested in the HCV polymerase assays that were staged to assess their effects on the formation of preelongation complex
(prebinding) or the elongation reaction carried out by the preelongation complex (postbinding). In the prebinding assay, increasing concentrations of peptides
were incubated with pOF1213 RNA substrate for 4 h at room temperature, followed by the addition of heparin and the nucleotide triphosphates. After 15
min, the reactions were stopped and quantitated. In the postbinding assay, the enzyme was incubated with the RNA substrate for 4 h at room temperature,
followed by incubation with increasing concentrations of peptides for 15 min. Heparin and nucleotide triphosphates were added followed by incubation for
15 min, after which the yield of products were determined. The numbers represent mean IC50 values in M.
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to the binding response complicates the interpretation of the
fit for this peptide and they appear to dominate the response
in the linear form of the peptide. Hence, it is possible that
the estimated Kd for NQW (S-S) could be lower than that
reported here. It should also be noted that the random amine
coupling procedure used to immobilize the enzyme to the
CM5 chip has the potential of modifying or obscuring the
suspected binding site of the peptides in an undetermined
percentage of the immobilized enzyme. If the Kd values of
the modified population of enzyme were weaker than the
true Kd, what in fact we would observe as a Kd would be an
average of the total population of enzyme. However, since
the weaker interactions contribute little to the overall re-
sponse, they probably would not affect the fitted Kd, whose
determination is not directly related to the absolute concen-
tration of active enzyme on the surface. As mentioned
previously, since the HCV NS5B interacted strongly with
the CM5 matrix, we were unable to do the preferred recip-
rocal binding experiment to measure the interaction be-
tween the native protein and the immobilized peptides.
More importantly, our results indicated that the con-
strained peptides NTW (S-S), KEY (S-S). NQW (S-S), and
the linear peptide NQW (L), which bound to the NS5B, also
inhibited the HCV NS5B enzyme activity in a selective
manner. Thus, there is a good correlation between the abil-
ity of the peptides to bind NS5B enzyme and their ability to
inhibit the enzyme activity in vitro. Given the high degree of
similarity in structure and function among other poly-
merases, the selective inhibition of the HCV polymerase
exhibited by these peptides supports the notion of selective
binding of the enzyme. It should be noted that the 50
g/ml BSA were included in the enzyme assays to mitigate
any nonspecific binding of peptide to the enzyme during the
course of the reaction. Since the linear peptides NTW (L)
and KEY (L) did not inhibit the enzyme activity, we suggest
that the tertiary peptide structure conferred by the disulfide
loop was essential for their inhibitory properties. In support
of this, the addition of DTT in the assays with NTW (S-S)
and KEY (S-S) led to a dramatic reduction of their inhibi-
tory property, likely due to the reduction of the disulfide
bond leading to conversion to the noninhibitory linear coun-
terparts (data not shown). In contrast, both the linear and the
constrained versions of the peptide NQW were able to bind
HCV polymerase and inhibit the enzyme activity in vitro. At
this point, it is not known whether these two peptides
inhibited the HCV polymerase activity through the same
binding pocket or a different binding site. Future work will
focus on cocrystalization of these peptides with the HCV
polymerase.
We have also addressed the amino acid requirement of
the peptides for NS5B inhibition, by alanine substitution
analysis of the heptamer sequence of the NTW (S-S) pep-
tide. The alanine scans of FPWGNTW showed that the F1
within the core motif was the most critical for the inhibitory
effect of the peptide. However, contributory effects of P2,
W3, N5, and W7 were noted, while G4 and T6 were ac-
commodated by A. The null effect of the G4-to-A change
may not be surprising since this can be considered a con-
servative change. Thus, we infer that the above-mentioned
residues could synergistically contribute to the inhibitory
property of the peptide. In addition, a measurable selective
inhibition with the constrained core motif FPWG (SS) was
observed, which indicates that this core sequence is critical
for the inhibitory property of the peptides (Table 2).
Our analysis indicated that these constrained peptides
blocked the formation of the preelongation complex, con-
sisting of HCV polymerase bound to the dinucleotide self-
primed RNA substrate, or a transition step required for the
preelongation complex to catalyze processive RNA synthe-
sis. Our data suggest that this is a slow or rate-limiting step
of the reaction. However, once the preelongation complex
was preformed, the peptide had no effect on RNA synthesis
catalyzed by this binary complex. Initial attempts to exam-
ine the effects of these peptides on the Huh7 cell-based
replicon were not successful due to the lack of an efficient
system to deliver the peptides into the cells. However,
recent advances on the generation of a cell-free replication
system may allow further characterization of the inhibitory
peptides described in the present study (Ali et al., 2002,
Hardy et al., 2003; Shi et al., 2003). During the last few
years, both nucleoside and nonnucleoside inhibitors for
HCV NS5B polymerase have been identified (Lesburg et
al., 2000). These compounds exhibited an in vitro anti-
NS5B activity with IC50 values in the micromolar range,
which is comparable to the values reported for the inhibitory
peptides in the present study. More recently, a class of
heterocyclic agent (benzo-1,2,4-thiadiazine) has been
shown to be a potent and highly specific inhibitor of NS5B
(Dhanak et. al., 2002; Gu, et al., 2003). This agent interacts
directly with NS5B apoenzyme as well as the RNA-bound
form of NS5B and inhibits RNA synthesis in a noncompet-
itive manner. The actual mechanism of peptide inhibition
needs to be clarified. It is likely that the peptides inhibited
enzyme activity when bound to a site that blocked an allo-
steric step required for enzyme function. We have shown that
Fig. 6. Inhibition of de novo synthesis of HCV polymerase by NTW(S-S)
peptide. In a 50 l reaction, 20 nM of the HCV polymerase was incubated
with 1.32 g/ml of poly (C) and 250 M GTP in presence of 0 to 40 M
of NTW(S-S) peptide. The reaction was incubated at 37°C for 2 h and
terminated with EDTA and the pmol GMP incorporated was determined as
described previously.
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the NTW (S-S) peptide inhibited the de novo synthesis cata-
lyzed by the enzyme, which suggests that it likely inhibited the
formation of a preinitiation complex between the enzyme and
the 3OH end of the linear poly (C) substrate. Unlike the
inhibition profile of the heterocyclic agent, the inability of the
peptides to block RNA synthesis by the binary complex (post-
binding data) suggests that these peptides might interfere with
the NS5B–template interaction to mediate inhibition.
The HCV polymerase is thought to function as a com-
plex with the nonstructural proteins and likely host factors
to facilitate viral genome replication in liver cells, or per-
missive cells, and current strategies are aimed toward de-
veloping therapeutics for inhibiting HCV genome replica-
tion. In principle, the NS5B polymerase or any of its
associated factors could be a target for small molecule
inhibitor development. The peptides identified in this study
are useful reagents to identify a binding pocket in the HCV
polymerase through cocrystallization studies and to further
probe the mechanism of enzyme function. By modeling
complementary interactions of the cocrystal structures of
the respective peptide:polymerase complex, it may be pos-
sible to obtain information useful in the rational design of
high-affinity binders that could potentially translate into the
design of small molecule inhibitors.
Materials and methods
Miscellaneous
The NS5B protein used in this study was derived from
the HCV BK strain, genotype 1b (Takamizawa et al., 1991).
The construction of NS5B with a 21 amino acid C-terminal
truncation, and a C-terminal hexahistidine tag, will be de-
scribed elsewhere (Olland, S., unpublished data). The pro-
tein was expressed in Escherichia coli and purified to ho-
mogeneity using Ni2 affinity chromatography, followed by
a porous heparin sepharose (HS) column. The final protein
preparation was 5 mg/ml in 50 mM Tris pH 7.5, 0.3 M
NaCl, 50% glycerol, 1 mM DTT and was 95% homoge-
neous based on mass spectometry analysis and SDS–PAGE
analysis (Olland et al., unpublished data). Protein concen-
tration was determined using the Bio-Rad reagent with
known BSA protein concentrations as reference standard as
described by the manufacturer. Disulfide constrained and
linear peptides of greater than 95% purity were synthesized
by Anaspec (CA). The peptides were dissolved in water or
DMSO for stocks of 2.5 or 5 mM, aliquoted as 25 l, and
stored at 70°C. Peptides were not used in experiments
after three freeze–thaw cycles.
Screening for peptide ligands of NS5B
The Ph.D-7-mer phage display constrained peptide li-
brary from New England BioLabs (Cat. No. 8110) was used
for the isolation of peptides that bind to NS5B according to
an optimized protocol described by the manufacturer. The
constrained library consisted of about 1.9  109 peptide
sequences with about 20 copies of each peptide in 10 l of
the supplied phage. About 1.5 g of NS5B (del 21-His) in
200 l of TBS was immobilized on Ni2-coated 96-well
plates (Pierce) for 2 h at 4°C by shaking gently. The wells
were washed twice with 200 l TBS buffer, and the plates
blocked with 250 l of TBS containing 5 mg/ml BSA
(Boehringer Mannheim Corp.) for 2 h at 4°C. Thereafter,
the wells were washed two times with 250 l of TBS buffer.
About 2 1011 phage particles in 200 l of TBS containing
0.01% Tween 20 were added to the wells, which were then
incubated at 23°C for 1 h. The wells were washed five times
with TBS containing 0.5% Tween to remove unbound
phages. The bound phage was eluted with 200 l of 0.2 M
glycine (pH 2.2) at room temperature for 6 min and imme-
diately neutralized with 1 M Tris pH 9.1. The phage was
amplified and titered, and the panning procedure repeated
three times, after which independent phage clones were
isolated. DNA were purified from 40 independent phage
isolates and the sequences corresponding to the displayed
peptides were determined.
Biacore analysis of peptide–NS5B interaction
Experiments to measure the interaction between the pep-
tides and NS5B polymerase by surface plasmon resonance
(SPR) were carried out on a Biacore 2000 instrument (Bia-
core Inc., Uppsala, Sweden). All sensor chips, coupling
reagents, and buffers were purchased from Biacore Inc.
Human serum albumin was obtained from Sigma Chemicals
(St. Louis, MO). The running and dilution buffer for all
operations was 10 mM HEPES, 150 mM NaCl, 3.4 mM
EDTA, 0.005% P20, pH 7.4. Coupling reactions were car-
ried out at flow rates of 5 l/min. All four channels of a
CM5 sensor chip were activated by a 7-min injection of a
mixture of 0.2 M N-ethyl-N-(3-diethyaminopropyl) carbo-
diimide (EDC) and 0.05 M N-hydroxysuccinimide (NHS).
The NS5B protein in a solution of 0.01 M sodium acetate,
pH 5.0, was injected over a single channel. Human serum
albumin in 0.01 M sodium acetate, pH 4.0, was injected in
a separate channel. No protein was injected in the remaining
two channels to provide two matrix background controls. A
typical binding level for both proteins was approximately
8000 resonance units (RU). Remaining esters were deacti-
vated by an injection of 1 M ethanolamine over all four
channels.
Peptides were injected over all four channels for 1 min at
a flow rate of 50 l/min. This provided sufficient time for
the interaction of peptide with NS5B to reach equilibrium.
Each peptide was injected over a range of concentrations
between 10 and 100 M. An equilibrium response was
recorded as the average value for the last 10 s of the
injection. A similar response from the control channel was
subtracted from this value to compensate for minor matrix
interactions and buffer mismatch. For samples that were
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diluted in DMSO, an additional correction factor generated
from a standard curve of various DMSO concentrations was
introduced as per Biacore’s recommendations.
Since RU is directly proportional to molecular weight,
the response of each peptide was converted to a molar
equivalent. The moles of peptide bound to the enzyme in a
particular injection were divided by the moles of NS5B
permanently immobilized on the chip. This value was plot-
ted versus the concentration of the injected peptide, which
allowed an evaluation of the stoichiometry of the interac-
tion. This curve was fitted with the steady-state affinity
model included in the Biacore Evaluation software to pro-
vide a dissociation constant (Kd). Off-rates were too rapid to
be measured reliably on the Biacore but appeared to be on
the order of 1 s1.
HCV NS5B polymerase assays
The HCV polymerase assays used in peptide evaluation
were carried out in 50 l containing 20 mM HEPES pH 7.5,
5 mM MgCl2, 1 mM DTT, 100 g/ml BSA, 20 units
Rnasein, 3% DMSO, 1 mM rATP, 4 mM rUTP, 0.08 mM
rCTP, and 0.05 mM and 2 Ci of [33P]rGTP (3000 Ci/
mmol, 10 mCi/ml) and 3 nM of the pOF1213 RNA substrate
(Baginski et al., 2000). Increasing concentrations of the
respective peptides were incubated with the enzyme for 15
min with the rNTPs, followed by the addition of pOF1213
RNA substrate and [33P]rGTP to start the reaction. The
reactions were incubated for 2 h at room temperature and
subsequently stopped by the addition of EDTA to 83 mM.
The IC50 values of peptides were determined from triplicate
samples using the Data Analysis Toolbox 1.0 from MDL
Information System Inc.
Burst assays that measured the elongation reaction cata-
lyzed by the NS5B enzyme were done in the presence or
absence of increasing concentrations of peptides under the
same buffer conditions as described above. For this assay,
the enzyme was preincubated with pOF1213 RNA for 4 h to
enrich for the binary preelongation complex, and the elon-
gation reaction was initiated by the addition of the 10 M
rNTPs containing 25 Ci [33P]rGTP (3000 Ci/mmol, 10
mCi/ml). Peptides were added either during the incubation
period of NS5B with pOF1213 (peptide prebinding) or after
the preincubation period (peptide postbinding). The reac-
tions were stopped at different times by the addition of
EDTA to 83 mM.
The de novo synthesis assay with NS5B polymerase was
performed in 50 l containing 20 mM HEPES (pH 7.5), 5
mM MgCl2, 20 nM NS5B enzyme, 1.32 g/ml Poly(C)
(Sigma), 20 U Rnasin, 50 g/ml BSA, 0–40 M of peptide,
250 M rGTP, and 2.5 Ci [33P]rGTP (3000 Ci/mmol, 10
mCi/ml). Reactions were incubated at 37°C for 120 min and
stopped with 10 l of 0.5 M EDTA. Samples were captured
on 96-well DEAE filters (Millipore) by filtration and
washed five times with 250 l of 0.5 M NaPO4 buffer (pH
7.0). The plates were air-dried for 10 min and 50 l of
Scintisafe Plus 50% (Fisher Scientific) was added for scin-
tillation counting using a beta-counter (Wallac).
Assays for calf thymus polymerase , human polymerase
, RSV polymerase, and HIV reverse transcriptase
All assays for the polymerases to be described were
carried out at their respective Kms of NTPs and nucleic acid
substrates. The calf thymus polymerase  assay was carried
out in a 50 l reaction containing 60 mM Tris pH 8, 5 mM
Mg acetate, 0.3 mg/ml BSA, 1 mM DTT, 0.1 mM spermi-
dine, 12 M dATP, 1.2 M dCTP, 1.5 M dGTP, 2.7 M
dTTP, 0.1 u enzyme, 0.5 Ci [33P]dCTP (NEN, 3000
Ci/mmol, 10 mCi/ml), and 0.54 g calf thymus DNA (Phar-
macia) for 2 h at room temperature. The human polymerase
 assay was carried out in 50 l of reaction containing 50
mM Tris pH 8.8, 10 mM MgCl2, 100 mM KCl, 0.4 mg/ml
BSA, 1 mM DTT, 1% glycerol, 5 M dATP, 10 M dCTP,
4 M dGTP, and 16 M dTTP, 0.04 u (1 g) polymerase
(Trevigen), 0.75 g CT DNA (Sigma), and 0.5 Ci
[33P]dATP (3000 Ci/mmol, 10 mCi/ml) for 2 h at room
temperature. The HIV RT assay was carried out in 20 l
reaction containing 50 mM Tris pH 8, 75 mM KCl, 3 mM
MgCl2, 1 mM DTT, 1.2 M dATP, 0.7 M dGTP, 0.18 M
dCTP, 0.8 M dTTP, 0.36 l primer:template stock (Ori-
gen), 10 u RNAsein (Promega), 0.25 Ci [33P]dCTP
(NEN, 3000 Ci/mmol, 10 mCi/ml), 50 g/ml BSA, 0.007 u
(0.82 g) RT (Worthington) at room temperature for 2 h.
The RSV polymerase (kindly provided by Dr. Clayton
Huntley) reaction was carried out in 60 l containing 50
mM HEPES/KOH pH 8, 100 mM KOAc, 5 mM MgOAc,
5% glycerol, 1 mM DTT, 0.75 g/ml Actinomycin D, 1
mM ATP, 140 M GTP, 100 M UTP, 1 M CTP, 0.25
Ci [33P]CTP, and 0.2 l (1 g) of RSV polymerase
preparation at room temperature for 2 h.
All reactions were quenched with 0.1 M EDTA, captured
on 96-well DEAE filters (Millipore) by filtration, and
washed five times with 250 l of 0.5 M NaPO4 buffer (pH
7.0). The plates were air-dried for 10 min and 50 l of
Scintisafe Plus 50% (Fisher Scientific) was added for scin-
tillation counting using a beta-counter (Wallac).
Agarose gel analysis of RNA products from burst reaction
Burst reactions were stopped with equal volumes of
phenol:chloroform (1:1) and precipitated with 10 g of
glycogen, 1/10 volume of 3 M sodium acetate, and 2.5
volume of ethanol at 70°C for 2 h. Samples were centri-
fuged at 15,000 rpm for 15 min at 4°C to collect the RNA
pellet. The RNA pellet was gently rinsed with 75% ethanol
and subsequently recovered by centrifugation. The pellet
was air dried and resuspended into 10 l of 1 Glyoxal
Loading dye (Ambion), heated at 85°C for 10 min, and
subjected to electrophoresis on a 2% glyoxal agarose gel
using NorthernMax Gly/gel Prep Running Buffer (Am-
bion). The gel was dried and exposed to X-OMAT film with
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a screen overnight. For quantitative analysis the gel was
exposed to Kodak K-screen for 4 h and scanned using a
Bio-Rad phosphorImager.
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